Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1962 1
1965 1
1969 1
1976 1
1982 1
1990 1
1998 2
1999 1
2005 1
2007 2
2008 1
2009 1
2014 1
2016 3
2017 3
2018 1
2020 2
2021 2
2022 2
2023 5
2024 6
2025 4
2026 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

43 results

Results by year

Filters applied: . Clear all
Page 1
A Phase 3 Trial of Inebilizumab in Generalized Myasthenia Gravis.
Nowak RJ, Benatar M, Ciafaloni E, Howard JF Jr, Leite MI, Utsugisawa K, Vissing J, Rojavin M, Li Q, Tang F, Wu Y, Rampal N, Cheng S; MINT Investigators. Nowak RJ, et al. N Engl J Med. 2025 Jun 19;392(23):2309-2320. doi: 10.1056/NEJMoa2501561. Epub 2025 Apr 8. N Engl J Med. 2025. PMID: 40202593 Clinical Trial.
Tolebrutinib in Nonrelapsing Secondary Progressive Multiple Sclerosis.
Fox RJ, Bar-Or A, Traboulsee A, Oreja-Guevara C, Giovannoni G, Vermersch P, Syed S, Li Y, Vargas WS, Turner TJ, Wallstroem E, Reich DS; HERCULES Trial Group. Fox RJ, et al. N Engl J Med. 2025 May 15;392(19):1883-1892. doi: 10.1056/NEJMoa2415988. Epub 2025 Apr 8. N Engl J Med. 2025. PMID: 40202696 Clinical Trial.
Tolebrutinib versus Teriflunomide in Relapsing Multiple Sclerosis.
Oh J, Arnold DL, Cree BAC, Ionete C, Kim HJ, Sormani MP, Syed S, Chen Y, Maxwell CR, Benoit P, Turner TJ, Wallstroem E, Wiendl H; Tolebrutinib Phase 3 GEMINI 1 and 2 Trial Group. Oh J, et al. N Engl J Med. 2025 May 15;392(19):1893-1904. doi: 10.1056/NEJMoa2415985. Epub 2025 Apr 8. N Engl J Med. 2025. PMID: 40202623 Clinical Trial.
Safety, tolerability, and efficacy of subcutaneous efgartigimod in patients with chronic inflammatory demyelinating polyradiculoneuropathy (ADHERE): a multicentre, randomised-withdrawal, double-blind, placebo-controlled, phase 2 trial.
Allen JA, Lin J, Basta I, Dysgaard T, Eggers C, Guptill JT, Gwathmey KG, Hewamadduma C, Hofman E, Hussain YM, Kuwabara S, Le Masson G, Leypoldt F, Chang T, Lipowska M, Lowe M, Lauria G, Querol L, Simu MA, Suresh N, Tse A, Ulrichts P, Van Hoorick B, Yamasaki R, Lewis RA, van Doorn PA; ADHERE Study Group. Allen JA, et al. Lancet Neurol. 2024 Oct;23(10):1013-1024. doi: 10.1016/S1474-4422(24)00309-0. Lancet Neurol. 2024. PMID: 39304241 Clinical Trial.
Safety and efficacy of evobrutinib in relapsing multiple sclerosis (evolutionRMS1 and evolutionRMS2): two multicentre, randomised, double-blind, active-controlled, phase 3 trials.
Montalban X, Vermersch P, Arnold DL, Bar-Or A, Cree BAC, Cross AH, Kubala Havrdova E, Kappos L, Stuve O, Wiendl H, Wolinsky JS, Dahlke F, Le Bolay C, Shen Loo L, Gopalakrishnan S, Hyvert Y, Javor A, Guehring H, Tenenbaum N, Tomic D; evolutionRMS investigators. Montalban X, et al. Lancet Neurol. 2024 Nov;23(11):1119-1132. doi: 10.1016/S1474-4422(24)00328-4. Epub 2024 Sep 19. Lancet Neurol. 2024. PMID: 39307151 Clinical Trial.
Long-Term Safety and Efficacy of Eculizumab in Aquaporin-4 IgG-Positive NMOSD.
Wingerchuk DM, Fujihara K, Palace J, Berthele A, Levy M, Kim HJ, Nakashima I, Oreja-Guevara C, Wang KC, Miller L, Shang S, Sabatella G, Yountz M, Pittock SJ; PREVENT Study Group. Wingerchuk DM, et al. Ann Neurol. 2021 Jun;89(6):1088-1098. doi: 10.1002/ana.26049. Epub 2021 Feb 27. Ann Neurol. 2021. PMID: 33586143 Free PMC article. Clinical Trial.
[Primary progressive multiple sclerosis: current issues of timely diagnosis].
Popova EV, Boyko AN, Barabanova MA, Antipova LN, Bakhtiyarova KZ, Belova AN, Solovieva VS, Belskaya GN, Lukashevich IG, Nikolaeva LI, Volkova LI, Turova EL, Kraeva AV, Goncharova ZA, Malkova NA, Poverennova IE, Sivertseva SA, Zhelnin AV, Trushnikova TN, Khabirov FA, Khaibullin TI. Popova EV, et al. Among authors: goncharova za. Zh Nevrol Psikhiatr Im S S Korsakova. 2017;117(10. Vyp. 2):35-40. doi: 10.17116/jnevro201711710235-40. Zh Nevrol Psikhiatr Im S S Korsakova. 2017. PMID: 29359731 Review. Russian.
[Results of 4 years of therapy with divozilimab in patients with relapsing multiple sclerosis].
Boyko AN, Alifirova VM, Goncharova ZA, Greshnova IV, Zaslavsky LG, Kotov SV, Mishin GN, Parshina EV, Poverennova IY, Sivertseva SA, Totolyan NA, Trinitatsky YV, Trushnikova TN, Sokolova IA, Shukin IA, Dudin VA, Pokhabov DV, Krasnova MV, Porozova AA, Eremeeva AV, Linkova YN, Zinkina-Orikhan AV. Boyko AN, et al. Among authors: goncharova za. Zh Nevrol Psikhiatr Im S S Korsakova. 2025;125(7. Vyp. 2):51-59. doi: 10.17116/jnevro202512507251. Zh Nevrol Psikhiatr Im S S Korsakova. 2025. PMID: 40779521 Clinical Trial. Russian.
43 results